North America Antiviral Drugs Market Size & Outlook
North America antiviral drugs market, 2018-2030 (US$M)
Related Markets
North America antiviral drugs market highlights
- The North America antiviral drugs market generated a revenue of USD 30,235.9 million in 2022.
- The market is expected to grow at a CAGR of -2% from 2023 to 2030.
- In terms of segment, hiv was the largest revenue generating application in 2022.
- Herpes is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2023 to 2030.
North America data book summary
| Market revenue in 2022 | USD 30,235.9 million |
| Market revenue in 2030 | USD 25,674.2 million |
| Growth rate | -2% (CAGR from 2022 to 2030) |
| Largest segment | Hiv |
| Fastest growing segment | Herpes |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | HIV, Hepatitis, Herpes, Influenza |
| Key market players worldwide | Roche Holding AG, GSK PLC ADR, AbbVie Inc, Merck & Co Inc, Johnson & Johnson, Bristol-Myers Squibb Co, Dr Reddy's Laboratories Ltd ADR, Aurobindo Pharma |
Other key industry trends
- In terms of revenue, North America region accounted for 41.5% of the global antiviral drugs market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 8,502.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antiviral Drugs Market Scope
Antiviral Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America antiviral drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antiviral drugs market will help companies and investors design strategic landscapes.
Hiv was the largest segment with a revenue share of 34.3% in 2022. Horizon Databook has segmented the North America antiviral drugs market based on hiv, hepatitis, herpes, influenza covering the revenue growth of each sub-segment from 2018 to 2030.
North America leads the global antiviral drugs market in terms of revenue generation, owing to the launch of effective products and technologically advanced production facilities in the region. In addition, the increasing prevalence of diseases, such as tuberculosis, RSV, influenza A & B, and COVID-19, is expected to drive market growth.
For instance, according to CDC, in the flu season of 2021–2022, influenza was estimated to affect 9 million people. Furthermore, the increasing number of strategic partnerships among manufacturers and companies for developing novel therapeutics is anticipated to drive market growth.
For instance, in December 2021, Merck partnered with Ridgeback Biotherapeutics and received FDA approval for molnupiravir, an oral antiviral authorized for emergency use to treat mild to moderate COVID-19.
Reasons to subscribe to North America antiviral drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America antiviral drugs market databook
-
Our clientele includes a mix of antiviral drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America antiviral drugs market , including forecasts for subscribers. This continent databook contains high-level insights into North America antiviral drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America antiviral drugs market size, by country, 2018-2030 (US$M)
North America Antiviral Drugs Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
